Podcasts about Ascent

Please enjoy this interview with Gene Ang, Ada Pfotenhauer, and Robert Urbonas.  Gene talks with Ada and Robert about their experience on the Kilimanjaro 2026: the Ascent tour.  They discuss their preparation for the trek, the highlights of the trek, their experience of the ascent night, the results of the descent portion, and their experience of the Maasai village.

Support Us: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://libri-vox.org/donateThe Ascent of Mount Carmel (Part 1)Saint John of the Cross (1542 - 1591)Translated by David Lewis (1814 - 1895)The Ascent of Mount Carmel is one of the timeless classics of Christian contemplation, radical in its time and deeply influential in the world today. St John of the Cross and St Teresa of Avila worked together to reform the Carmelite Order in the Roman Catholic Church, in which he is honored as one of the Doctors of the Church. An active priest and teacher in his lifetime, this work is considered primary source material the training of Spiritual Directors, and an essential set of guidelines for all students of Revelation through Divine Love. Read by ( Ed Humpal)Genre(s): Christianity - OtherLanguage: EnglishKeyword(s): christian (192), mysticism (40), spiritual life (7), roman catholic (6), camelite (2), divine love (2), spiritual direction (1), divine union (1), apophatic theology (1)Support Us: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://libri-vox.org/donate

Support Us: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://libri-vox.org/donateThe Ascent of Mount Carmel (Part 2)⁠Saint John of the Cross (1542 - 1591)⁠Translated by ⁠David Lewis (1814 - 1895)⁠The Ascent of Mount Carmel is one of the timeless classics of Christian contemplation, radical in its time and deeply influential in the world today. St John of the Cross and St Teresa of Avila worked together to reform the Carmelite Order in the Roman Catholic Church, in which he is honored as one of the Doctors of the Church. An active priest and teacher in his lifetime, this work is considered primary source material the training of Spiritual Directors, and an essential set of guidelines for all students of Revelation through Divine Love. Read by ( Ed Humpal)Genre(s): Christianity - OtherLanguage: EnglishKeyword(s): ⁠christian⁠ (192), ⁠mysticism⁠ (40), ⁠spiritual life⁠ (7), ⁠roman catholic⁠ (6), ⁠camelite⁠ (2), ⁠divine love⁠ (2), spiritual direction (1), divine union (1), apophatic theology (1)Support Us: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://libri-vox.org/donate

The air thins with each step, and talking becomes almost impossible without a rest. The mountain is relentless, and so are those intent on beating it. Reaching the peak requires patience and knowing which route to take and what to leave behind. No one climbs alone, and no one fails alone either. The summit awaits and promises unmatched Tranquility: The Ascent by James Emmerson from Lucky Duck Games with art by Tristam Rossin.Read the full review here: https://tabletopgamesblog.com/2026/02/14/tranquility-the-ascent-saturday-review/Useful LinksTranquility: The Ascent: https://luckyduckgames.com/global/game/795-tranquility-the-ascentRulebook: https://website.cdn77.luckyduckgames.com/downloads/August2024/d4e4f20a1fa3776f1b151ad781c843b4.pdfLucky Duck Games: https://luckyduckgames.com/global/BGG listing: https://boardgamegeek.com/boardgame/334717/tranquility-the-ascentTranquility: The Descent review: https://tabletopgamesblog.com/2025/10/18/tranquility-the-descent-saturday-review/MusicIntro Music: Bomber (Sting) by Riot (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/audiolibrary/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠)Sound Effects: ZapSplat (https://www.zapsplat.com/)Music: Nature 4 [nature documentary series]Produced by Sascha EndeLink: https://ende.app/en/song/13308-nature-4-nature-documentary-seriesMusic: Epic Drone Shots 004Produced by Sascha EndeLink: https://ende.app/en/song/12291-epic-drone-shots-004SupportIf you want to support this podcast financially, please check out the links below:Ko-Fi: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://ko-fi.com/TabletopGamesBlog⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Patreon: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/tabletopgamesblog⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Website: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://tabletopgamesblog.com/support/⁠⁠⁠

Hi Everyone,Please enjoy this discussion with myself and Louis Green who went on the Kilimanjaro 2026: the Ascent Trek.  We discuss his experience on the trek, his motivations, insights, and integration back into his daily life on the return.Thanks so much!Gene

AEW's Brody King scored a MASSIVE win against MJF on AEW Dynamite, Drew McIntyre has Cody Rhodes, Jacob Fatu, Sami Zayn, Randy Orton, and more circling around him ahead of Elimination Chamber! Who does he face? Also, we dive into the latest stories in TNA with Steve Maclin TURNING on Mike Santana!? Why would he do that and how could this be tied with The System and Moose?! WELCOME BACK TO REBOOKED!⏰ Subscribe to the channel to be alerted! https://www.youtube.com/@REBOOKEDWrestling?sub_confirmation=1

The Rebbe responds to concerns about spiritual decline in a ma'abarah despite establishing two synagogues. He emphasizes that in Eretz HaKodesh—“Palterin Shel Melech”—there must be growth, not decline. Aliyah obligates added kedushah and elevation, and he urges inspiring others toward practical daily improvement. https://www.torahrecordings.com/rebbe/igroskodesh/016/005/6063

Choosing the follow Jesus is the best decision you could ever make.

Have you ever felt like a spectator in your spiritual life, watching from the sidelines while others experience God's presence? Pastor Dave challenges us to move beyond observation into authentic participation, revealing how true worship isn't about personality but about positioning our hearts before God. Through powerful biblical examples—from Jehoshaphat's victory through praise to Paul and Silas's midnight worship—he shows how God consistently responds to genuine worship with breakthrough, freedom, and transformation. Whether you're seeking deeper connection or facing impossible walls, this message inspires: God responds when we worship. Watch now to discover how your praise can shake foundations and unlock chains!Psalms 150Praise the Lord! Praise God in His sanctuary; Praise Him in His mighty firmament!2 Praise Him for His mighty acts; Praise Him according to His excellent greatness!3 Praise Him with the sound of the trumpet; Praise Him with the lute and harp!4 Praise Him with the timbrel and dance; Praise Him with stringed instruments and flutes!5 Praise Him with loud cymbals; Praise Him with clashing cymbals!6 Let everything that has breath praise the Lord.2 Chronicles 20 It happened after this that the people of Moab with the people of Ammon, and others with them besides the Ammonites, came to battle against Jehoshaphat. 2 Then some came and told Jehoshaphat, saying, “A great multitude is coming against you from beyond the sea, from Syria; and they are in Hazazon Tamar” (which is En Gedi). 3 And Jehoshaphat feared, and set himself to seek the Lord, and proclaimed a fast throughout all Judah. 4 So Judah gathered together to ask help from the Lord; and from all the cities of Judah they came to seek the Lord.5 Then Jehoshaphat stood in the assembly of Judah and Jerusalem, in the house of the Lord, before the new court, 6 and said: “O Lord God of our fathers, are You not God in heaven, and do You not rule over all the kingdoms of the nations, and in Your hand is there not power and might, so that no one is able to withstand You? 7 Are You not our God, who drove out the inhabitants of this land before Your people Israel, and gave it to the descendants of Abraham Your friend forever? 8 And they dwell in it, and have built You a sanctuary in it for Your name, saying, 9 ‘If disaster comes upon us—sword, judgment, pestilence, or famine—we will stand before this temple and in Your presence (for Your name is in this temple), and cry out to You in our affliction, and You will hear and save.' 10 And now, here are the people of Ammon, Moab, and Mount Seir—whom You would not let Israel invade when they came out of the land of Egypt, but they turned from them and did not destroy them— 11 here they are, rewarding us by coming to throw us out of Your possession which You have given us to inherit. 12 O our God, will You not judge them? For we have no power against this great multitude that is coming against us; nor do we know what to do, but our eyes are upon You.”13 Now all Judah, with their little ones, their wives, and their children, stood before the Lord.14 Then the Spirit of the Lord came upon Jahaziel the son of Zechariah, the son of Benaiah, the son of Jeiel, the son of Mattaniah, a Levite of the sons of Asaph, in the midst of the assembly. 15 And he said, “Listen, all you of Judah and you inhabitants of Jerusalem, and you, King Jehoshaphat! Thus says the Lord to you: ‘Do not be afraid nor dismayed because of this great multitude, for the battle is not yours, but God's. 16 Tomorrow go down against them. They will surely come up by the Ascent of Ziz, and you will find them at the end of the brook before the Wilderness of Jeruel. 17 You will not need to fight in this battle. Position yourselves, stand still and see the salvation of the Lord, who is with you, O Judah and Jerusalem!' Do not fear or be dismayed; tomorrow go out against them, for the Lord is with you.”18 And Jehoshaphat bowed his head with his face to the ground, and all Judah and the inhabitants of Jerusalem bowed before the Lord, worshiping the Lord.19 Then the Levites of the children of the Kohathites and of the children of the Korahites stood up to praise the Lord God of Israel with voices loud and high.20 So they rose early in the morning and went out into the Wilderness of Tekoa; and as they went out, Jehoshaphat stood and said, “Hear me, O Judah and you inhabitants of Jerusalem: Believe in the Lord your God, and you shall be established; believe His prophets, and you shall prosper.” 21 And when he had consulted with the people, he appointed those who should sing to the Lord, and who should praise the beauty of holiness, as they went out before the army and were saying:“Praise the Lord,For His mercy endures forever.”22 Now when they began to sing and to praise, the Lord set ambushes against the people of Ammon, Moab, and Mount Seir, who had come against Judah; and they were defeated. 23 For the people of Ammon and Moab stood up against the inhabitants of Mount Seir to utterly kill and destroy them.23 For the people of Ammon and Moab stood up against the inhabitants of Mount Seir to utterly kill and destroy them. And when they had made an end of the inhabitants of Seir, they helped to destroy one another.24 So when Judah came to a place overlooking the wilderness, they looked toward the multitude; and there were their dead bodies, fallen on the earth. No one had escaped.25 When Jehoshaphat and his people came to take away their spoil, they found among them an abundance of valuables on the dead bodies, and precious jewelry, which they stripped off for themselves, more than they could carry away; and they were three days gathering the spoil because there was so much.Joshua 6 Now Jericho was securely shut up because of the children of Israel; none went out, and none came in.2 And the Lord said to Joshua: “See! I have given Jericho into your hand, its king, and the mighty men of valor. 3 You shall march around the city, all you men of war; you shall go all around the city once. This you shall do six days. 4 And seven priests shall bear seven trumpets of rams' horns before the ark. But the seventh day you shall march around the city seven times, and the priests shall blow the trumpets. 5 It shall come to pass, when they make a long blast with the ram's horn, and when you hear the sound of the trumpet, that all the people shall shout with a great shout; then the wall of the city will fall down flat. And the people shall go up every man straight before him.”6 Then Joshua the son of Nun called the priests and said to them, “Take up the ark of the covenant, and let seven priests bear seven trumpets of rams' horns before the ark of the Lord.” 7 And he said to the people, “Proceed, and march around the city, and let him who is armed advance before the ark of the Lord.”8 So it was, when Joshua had spoken to the people, that the seven priests bearing the seven trumpets of rams' horns before the Lord advanced and blew the trumpets, and the ark of the covenant of the Lord followed them. 9 The armed men went before the priests who blew the trumpets, and the rear guard came after the ark, while the priests continued blowing the trumpets. 10 Now Joshua had commanded the people, saying, “You shall not shout or make any noise with your voice, nor shall a word proceed out of your mouth, until the day I say to you, ‘Shout!' Then you shall shout.” 11 So he had the ark of the Lord circle the city, going around it once. Then they came into the camp and lodged in the camp.12 And Joshua rose early in the morning, and the priests took up the ark of the Lord. 13 Then seven priests bearing seven trumpets of rams' horns before the ark of the Lord went on continually and blew with the trumpets. And the armed men went before them. But the rear guard came after the ark of the Lord, while the priests continued blowing the trumpets. 14 And the second day they marched around the city once and returned to the camp. So they did six days.15 But it came to pass on the seventh day that they rose early, about the dawning of the day, and marched around the city seven times in the same manner. On that day only they marched around the city seven times. 16 And the seventh time it happened, when the priests blew the trumpets, that Joshua said to the people: “Shout, for the Lord has given you the city! 17 Now the city shall be doomed by the Lord to destruction, it and all who are in it. Only Rahab the harlot shall live, she and all who are with her in the house, because she hid the messengers that we sent. 18 And you, by all means abstain from the accursed things, lest you become accursed when you take of the accursed things, and make the camp of Israel a curse, and trouble it. 19 But all the silver and gold, and vessels of bronze and iron, are [b]consecrated to the Lord; they [c]shall come into the treasury of the Lord.”20 So the people shouted when the priests blew the trumpets. And it happened when the people heard the sound of the trumpet, and the people shouted with a great shout, that the wall fell down flat. Then the people went up into the city, every man straight before him, and they took the city.Acts 16:25 But at midnight Paul and Silas were praying and singing hymns to God, and the prisoners were listening to them. 26 Suddenly there was a great earthquake, so that the foundations of the prison were shaken; and immediately all the doors were opened and everyone's chains were loosed.27 And the keeper of the prison, awaking from sleep and seeing the prison doors open, supposing the prisoners had fled, drew his sword and was about to kill himself. 28 But Paul called with a loud voice, saying, “Do yourself no harm, for we are all here.”29 Then he called for a light, ran in, and fell down trembling before Paul and Silas. 30 And he brought them out and said, “Sirs, what must I do to be saved?”31 So they said, “Believe on the Lord Jesus Christ, and you will be saved, you and your household.”32 Then they spoke the word of the Lord to him and to all who were in his house. 33 And he took them the same hour of the night and washed their stripes. And immediately he and all his family were baptized.

Life often leaves us feeling spiritually lost and disconnected, like we're living in a desert. As believers, we are pilgrims on a journey toward spiritual growth, but this requires honest self-assessment of our spiritual condition. We must ask ourselves difficult questions about whether we're connected or isolated, authentic or fake, growing or stagnant. Modern culture's emphasis on instant gratification makes spiritual growth more challenging, as it requires patience and delayed rewards. Psalm 120 shows us that spiritual journeys often begin in distress, not comfort. The key is bringing our honest struggles to God in prayer, remembering His past faithfulness, and choosing to keep moving forward spiritually regardless of circumstances.

No podcast do Balde do Odo de hoje, Luiz “Morn” Castanheira e Mariana “Kira” Gamberger recebem o convidado Fernando “Odo” Rodrigues para discutir sobre o nono episódio da quinta temporada de Deep Space Nine, “The Ascent”. Odo recebe a missão de levar Quark para um julgamento, que ele interpreta como Quark sendo um dos acusados e passa boa parte do tempo tentando tirar do Quark que delito ele cometeu. No meio do caminho o runabout apresenta problemas, por ter sido sabotado e eles caem num planeta inóspito. Apesar das diferenças eles meio que tem que trabalhar juntos para conseguirem sair dali. Enquanto isso, na Estação, Nog volta da Academia da Frota e ele e Jake vão morar juntos. Mas nem tudo são flores. Ouça em nosso player agora ou baixe nos agregadores de podcast. [redes] Para saber mais sobre Deep Space Nine, acesse o Guia de Episódios de Deep Space Nine! O post Balde do Odo #109 The Ascent apareceu primeiro em Trek Brasilis.

En este episodio especial de BreastLink, el Dr. Juan Carlos Samamé, oncólogo médico de Lima, Perú, y vicepresidente de la Latin American Breast Cancer Association (LABCA), recibe al Dr. Antonio Llombart Cussac, jefe de servicio del Hospital Arnau de Vilanova y coordinador en la Universidad Cardenal Herrera en Valencia, España, y al Dr. Fernando Petracci, oncólogo médico y jefe de Oncología de la Clínica San Camilo en Buenos Aires, Argentina. Juntos presentan un análisis de los avances más relevantes del 2025 en cáncer de mama.Cáncer de mama HER2+:DESTINY-Breast05DESTINY-Breast11neoCARHPDESTINY-Breast09 Cáncer de mama luminal:lidERA Breast CancerEMBER-3EPIK-B5ELEVATEevERAVIKTORIA-1SERENA-6INAVO120CAPITello-291Cáncer de mama triple negativo:ASCENT-04/KEYNOTE-D19ASCENT3TROPION-Breast02Material exclusivo para profesionales de la salud. Este material ha sido desarrollado únicamente con fines educativos e informativos y no tiene la intención de sustituir el juicio clínico de los profesionales de la salud.Las opiniones y declaraciones presentadas en este contenido son responsabilidad exclusiva de los ponentes y no reflejan necesariamente la postura institucional de ScienceLink ni de terceros mencionados. La información presentada se basa en el conocimiento y la experiencia profesional de los ponentes. La veracidad, exactitud y actualidad científica de los datos son de su exclusiva responsabilidad. Así mismo garantizan que el contenido utilizado no infringe derechos de autor de terceros y asumen toda responsabilidad por su uso.Se deberán de revisar las indicaciones aprobadas en el país con estricto apego al marco regulatorio aplicable para cada uno de los tratamientos y medicamentos comentados.

Ger Gilroy, Colm Boohig and Arthur James O'Dea were back in studio this morning with all manner of major sports stories to chat through. After an initial diversion to consider the quality of Marco Pierre White's steaks (and his writing ability), they got stuck into hurling's manliness, Arsenal's doggedness and the dangers (or joy) of sporting nostalgia. The conversation ends just as we started talking to Pat Nevin about last night's League Cup semi-final second leg clash between Arsenal and Chelsea, but if you want to hear that you'll need to be an OTB member! Enjoy! Catch The Off The Ball Breakfast show LIVE weekday mornings from 7:30am or just search for Off The Ball Breakfast and get the podcast on the Off The Ball app.SUBSCRIBE at OffTheBall.com/joinOff The Ball Breakfast is live weekday mornings from 7:30am across Off The Ball

This week, Pastor Abraham leads us through Psalm 123. The latest piece in our Psalms of Ascent series. Join us this week for our last service at 15 W 86th St before we move to our new home on 57th St!

What if your hotel could know exactly what your guests want before they even check in — and deliver it automatically? In this episode, David Millili and Steve Carran sit down with Scott Buelter, CEO of Ascent 360, to dive into the transformative power of AI, data, and personalization in the hospitality industry.In this episode you'll learn about:How hotels are using Customer Data Platforms (CDPs) to unify guest data from multiple systems.The current and future role of AI in hospitality, from marketing automation to operational efficiency.How AI can support staff rather than replace them, improving the human touch in guest interactions.The shift from providing tools to delivering outcomes, and why marketers who embrace AI will thrive.If you want to understand how AI and data are shaping the next generation of hotel marketing, guest experiences, and operational efficiency, this episode is a must-watch.Watch the FULL EPISODE on YouTube: https://youtu.be/wM8cOSoRIXsThis episode is sponsored by Ascent360: https://ascent360.com/ Links:Scott on LinkedIn: https://www.linkedin.com/in/scottbuelter/Ascent360: https://ascent360.com/For full show notes head to: https://themodernhotelier.com/episode/247Follow on LinkedIn: https://www.linkedin.com/company/the-...Join the conversation on today's episode on The Modern Hotelier LinkedIn pageConnect with Steve and David:Steve: https://www.linkedin.com/in/%F0%9F%8E...David: https://www.linkedin.com/in/david-mil.

Deep in the woods at our very own Bush of Ghosts stage at Watching Trees, Scottish producer Brian d'Souza, aka Auntie Flo, brought his ‘Plants Can Dance' project to life in a five-hour ambient set beneath a canopy of trees. Drawing from the playlists he's been curating for Imperial College's psychedelic therapy trials, d'Souza transformed the clearing into what he describes as “a sanctuary away from the main stage,” where human – and non-human – audiences alike could experience music designed to mirror the quiet intelligence of the natural world. This 90 min excerpt captures the heart of that nocturnal performance, guiding listeners through the Ascent, Peak, and Descent phases – a journey filtered from the vast database of ambient music d'Souza has amassed over five years of running Ambient Flo radio. The setting itself became integral to the experience: darkness creating a natural sensory deprivation that, as d'Souza notes, allows listeners to become “more absorbed in their other senses, including the sounds they hear.” At the core of d'Souza's ‘Sunflowers' next instalment for our Music To Watch Seeds series: auntieflo.bandcamp.com/album/music-to-watch-seeds-grow-by-007-brian-d-souza-sunflowers lies a profound botanical truth: sunflowers practice cooperation over competition. Recent research reveals that when these plants encounter nutrient-rich soil between neighbours, they deliberately root elsewhere to avoid conflict – a form of underground etiquette that challenges our traditional understanding of survival of the fittest. D'Souza's album captures this behaviour sonically, using biodata from his son's sunflower in their London garden, converted into sound through his modular synthesiser via Instruo's Scion module. This live performance extends that concept into the forest, where ambient music fulfils its original definition – having enough space to mix with environmental sounds, creating a novel soundscape at all times. As d'Souza reflects on Peter Wohlleben's ‘Hidden Life Of Trees' and its description of forests as interconnected social networks, the Bush of Ghosts set becomes a meditation on what he calls “the More Than Human world” – a space where silence represents the fragility of life, and where trees, unlike festival-goers, “aren't going to leave the dancefloor if they don't like a track.” The result is an invitation to forge a deeper connection with the natural world, to witness how plants can indeed dance. Full interview here: https://www.theransomnote.com/music/mixes/seeds-mix-8-brian-dsouza-live-bush-of-ghosts/ @auntie-flo @watching-trees

HOO boy, this one has been an odyssey. Between computer hardware failures, file corruption, ice storms, and assorted other real-world chaos, it's a bit of a surprise that this episode made it out at all, much less on time. But it's here! Join us as we talk about games where one or more players are looking to win the game in a completely different way from everyone else. Is Joe the first person ever to compare the Bene Gesserit to Babe Ruth? We think so. High praise: This game is "A fun expenditure of human time." We digress briefly into discussing Jubensha, the Chinese LARPy RPG craze that's making its way to the U.S. We learn of yet another massive gap in Mike's geek culture experience. Frank tells us about "Nemesis - the party game!" Do you have any favorite examples of games with weird alternate victory conditions? Come visit our Discord server to chat with us and other like-minded game nerds! As always, thank you for listening. Please consider writing us an iTunes review if you like what you hear! We'd also love to have you visit our website and let us know what kinds of games we should discuss next. You're also more than welcome to comment on the episode page, or our Discord, or our Facebook page, or tag @ascentofboardgames on Bluesky. Whatever way you prefer to share your opinions with us, we'd love to hear them.  As always, we appreciate your listening - stay safe out there, and happy gaming! Website: https://www.ascentofboardgames.com Email: ascentofboardgames@gmail.com Discord: https://discord.gg/tdH3QAn  Facebook: https://www.facebook.com/groups/ascentboardgames/ Bluesky: https://bsky.app/profile/ascentofboardgames.bsky.social Discord: http://discord.ascentofboardgames.com Instagram: https://www.instagram.com/ascentofboardgames/ And, very occasionally, Twitch: https://www.twitch.tv/ascentofboardgames Intro and outro music is "Evening Melodrama" by Kevin MacLeod (incompetech.com), licensed under a Creative Commons: By Attribution 3.0 License. The Ascent of Board Games is licensed under a Creative Commons Attribution 4.0 International License. Some rights reserved. Thank you for listening!

In today's episode, the discussion features Komal Jhaveri, MD, FACP, a breast medical oncologist at Memorial Sloan Kettering Cancer Center, who reviewed the evolving role of TROP2-directed antibody–drug conjugates (ADCs) in the management of hormone receptor (HR)–positive, HER2-negative metastatic breast cancer. She drew on findings from the phase 3 ASCENT-07 trial (NCT05840211), which evaluated sacituzumab govitecan-hziy (Trodelvy) in the first-line setting following endocrine therapy for patients with HR-positive, HER2-negative metastatic breast cancer.In this exclusive interview, Dr Jhaveri discussed the rationale for evaluating sacituzumab govitecan earlier in the treatment paradigm, summarized key efficacy outcomes from ASCENT-07, and contextualized why the trial did not meet its primary progression-free survival end point. She also highlighted how disease biology and patient selection may influence outcomes when ADCs are moved into earlier lines of therapy, and outlined practical considerations for toxicity management and future trial design as the TROP2 ADC landscape continues to evolve.asts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Mary Eden is known on Instagram as Trad Princess but in real life, she’s one of the sport’s best offwidth crack climbers. Recently she acheived the first female ascent of Century Crack, perhaps the world’s longest and hardest wide roof crack.  But first, we talk about what everyone's talking about. Alex Honnold and Taipei 101. To listen to the full intro bit, however, you’ll need to head over to Patreon.com/runoutpodcast to become a supporter of the show. With just a few more subscribers, we’ll make as much money as Honnold did free soloing Taipei. Today’s final bit comes from the heavy metal band Bygone, with Canmore-based climber Noah Stachulski on guitar. When Noah’s not contemplating dry-tooling ethics, he’s debating his music bros on how to classify different genres of metal. Little surprise these the two worlds go together so well. Show Notes Mary Eden Becomes First Woman to Send ‘Century Crack' (5.14b) https://www.climbing.com/news/mary-eden-trad-princess-first-female-ascent-century-crack/ Follow Mary Catherine Eden on Instagram https://instagram.com/tradprincess Alex Honnold Completes Historic Live Climb of Taipei 101 https://www.netflix.com/tudum/articles/how-to-watch-alex-honnold-skyscraper-climb-live-netflix Bygone on Spotify: https://open.spotify.com/artist/7ii5T8TaNV9XpG2mOkwslf?si=yqRUoJa3QzG11wC4oxoKKg Follow Noah Stachulski on Instagram: https://www.instagram.com/atthemountainsofradness/ Become a RunOut Rope Gun! Support our podcast and increase your RunOut runtime. Bonus episodes, AMA, and more will be available to our Rope Guns. Thank you for your support! http://patreon.com/runoutpodcast Contact us Send ideas, voicemail, feedback and more. andrew@runoutpodcast.com // chris@runoutpodcast.com

Today, we're looking into why city leaders are pushing for more penalties against the landlord of the South Portland ICE facility. We're also hearing about a gap in Portland's police oversight system and the city-commissioned study that recommends we move away from renovating the Keller Auditorium. Joining host Claudia Meza on this week's Friday news roundup are KBOO news director Althea Billings and our very own executive producer, John Notarianni. Discussed in Today's Episode: Columbia, Breakside Team Up for Beer Made With Bear Poop for the Super Bowl [KOIN] Portland Councilors Urge Mayor Wilson To Carry Out New Penalties on ICE Facility [OPB] Study Suggests Portland Should Not Renovate Keller Auditorium, Saying City Can't Support Two Large-Scale Entertainment Venues [KGW] Police Oversight in Portland Is Quietly Falling Apart Amid Transition to New Accountability System [KBOO] Landlord of Portland ICE Offices Admits He Was at the Wheel of a Mercedes That Struck a Protester [Willamette Week] Become a member of City Cast Portland today! Get all the details and sign up here.  Who would you like to hear on City Cast Portland? Shoot us an email at portland@citycast.fm, or leave us a voicemail at 503-208-5448. Want more Portland news? Then make sure to sign up for our morning newsletter and be sure to follow us on Instagram.  Looking to advertise on City Cast Portland? Check out our options for podcast and newsletter ads at citycast.fm/advertise. Learn more about the sponsors of this January 30th episode: The Ascent by Christopher Walker

In this podcast Kushal speaks with the former chief of R & AW Mr. Vikram Sood about his new book, "GREAT POWER GAMES : From Western Decline to Eastern Ascent." Follow Him: X: @Vikram_Sood Book: https://amzn.in/d/3Tiz4BJ #Trump #foreignpolicy #CIA #RAW #deepstate ------------------------------------------------------------ Listen to the podcasts on: SoundCloud: https://soundcloud.com/kushal-mehra-99891819 Spotify: https://open.spotify.com/show/1rVcDV3upgVurMVW1wwoBp Apple Podcasts: https://podcasts.apple.com/us/podcast/the-c%C4%81rv%C4%81ka-podcast/id1445348369 Stitcher: https://www.stitcher.com/show/the-carvaka-podcast ------------------------------------------------------------ Support The Cārvāka Podcast: Buy Kushal's Book: https://amzn.in/d/58cY4dU Become a Member on YouTube: https://www.youtube.com/channel/UCKPx... Become a Member on Patreon: https://www.patreon.com/carvaka UPI: kushalmehra@icici Interac Canada: kushalmehra81@gmail.com To buy The Carvaka Podcast Exclusive Merch please visit: http://kushalmehra.com/shop ------------------------------------------------------------ Follow Kushal: Twitter: https://twitter.com/kushal_mehra?ref_... Facebook: https://www.facebook.com/KushalMehraO... Instagram: https://www.instagram.com/thecarvakap... Koo: https://www.kooapp.com/profile/kushal... Inquiries: https://kushalmehra.com/ Feedback: kushalmehra81@gmail.com

Ben Ennis and Daniele Franceschi kick off the second hour alongside Amazon Prime NHL & MLB Network host, Adnan Virk! He dives into the Maple Leafs' recent struggles, the state of the current era, and the scrutiny surrounding Auston Matthews. The conversation then shifts to the Blue Jays as pitcher and catcher reporting approaches, including Vegas' AL East odds, the impact of losing Bo Bichette, and whether offseason additions could position Toronto as contenders once again. After the break, the guys are joined by Ty Dunne (23:17) of GoLongTD.com to discuss the Bills' hiring of Joe Brady, fan reaction to his introduction, changes within the organization, offseason priorities, and the state of Buffalo's Super Bowl window. The show closes with a comparison of leadership and accountability between Josh Allen and Auston Matthews.The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Sports & Media or any affiliates.

It has not felt like a normal winter in Portland. December was the warmest on record, January has been unusually dry, and people are already noticing plants blooming that usually don't show up for months. Today we're talking with Norther Emily of Wild Solitude Guiding to determine if this is weird-but-normal weather or a warning sign of bigger changes ahead. Become a member of City Cast Portland today! Get all the details and sign up here.  Who would you like to hear on City Cast Portland? Shoot us an email at portland@citycast.fm, or leave us a voicemail at 503-208-5448. Want more Portland news? Then make sure to sign up for our morning newsletter and be sure to follow us on Instagram.  Looking to advertise on City Cast Portland? Check out our options for podcast and newsletter ads at citycast.fm/advertise. Learn more about the sponsors of this January 29th episode The Ascent by Christopher Walker

Today on City Cast Portland, we have updates on the shooting that left two police officers injured, and more details on the Gresham family detained and sent to a Texas facility by border patrol agents. Plus, we get a firsthand account of what's going on with ICE in Minneapolis. Joining host Claudia Meza on this midweek roundup is our very own senior producer, Giulia Fiaoni, and City Cast Twin Cities creative producer Adam Sage. Discussed in Today's Episode: Portland Police Arrest Suspect in Shooting That Wounded 2 Officers [Oregonian] Gresham Family Detained by Immigration Officers While Seeking Medical Care for Their 7-Year-Old [OPB] Minnesota Is Under Occupation by Federal Agents From ICE and CBP, and We Need Your Support. [Stand with Minnesota] A Day of Strike and Protest in the Twin Cities [City Cast Twin Cities] City Cast Portland is looking for an Audience Development Manager. Go to ⁠citycast.fm/jobs⁠ for more information and to apply. Become a member of City Cast Portland today! Get all the details and sign up here.  Who would you like to hear on City Cast Portland? Shoot us an email at portland@citycast.fm, or leave us a voicemail at 503-208-5448. Want more Portland news? Then make sure to sign up for our morning newsletter and be sure to follow us on Instagram.  Looking to advertise on City Cast Portland? Check out our options for podcast and newsletter ads at citycast.fm/advertise. Learn more about the sponsor of this January 28th episode: The Ascent by Christopher Walker

This week, due to the snow storm in NYC, Pastor Abraham lead us into our next Psalm via zoom on our livestream channel. Quite a coincidence for a sermon on why it is important that we gather together in the house of the Lord. Join us next week at 9:30 & 11 AM to hear more on the Psalms of Ascent!

Next week, Oregon lawmakers are heading into a short, five-week legislative session with a very long to-do list. At the top of it is how to keep the state's transportation system from falling apart. Today on City Cast Portland, we're talking with Dirk VanderHart, OPB's state politics and government reporter. He's going to help us make sense of the options, the legal chaos, and what else lawmakers are trying to squeeze into this short session. Become a member of City Cast Portland today! Get all the details and sign up here.  Who would you like to hear on City Cast Portland? Shoot us an email at portland@citycast.fm, or leave us a voicemail at 503-208-5448. Want more Portland news? Then make sure to sign up for our morning newsletter and be sure to follow us on Instagram.  Looking to advertise on City Cast Portland? Check out our options for podcast and newsletter ads at citycast.fm/advertise. Learn more about the sponsor of this January 27th episode: The Ascent by Christopher Walker

Welcome to Part 4 of our 5-part mini-series, "The Ascent."It is easy to find peace when the ground is flat and the sun is shining, but life isn't always a meadow—sometimes it is a mountain. In today's session, we leave the comfort of the Open Field to face the incline, not to conquer the mountain, but to discover the strength that has been hiding in your heart all along.This guided meditation is designed to help you build resilience and navigate the "boulders" in your path—whether they are worries, fears, or difficult people. We will practice "Altitude Breathing" to oxygenate your courage and visualize a climb that shifts your perspective from the problem to the progress you have made.In this episode, we will cover:Altitude Breathing: A breathwork technique to calm panic when the path gets steep.The Boulder Visualization: Learning to navigate around obstacles rather than fighting them.The Plateau: Recognizing how far you have come.Peak Affirmations: Use these affirmations when you feel the weight of the climb:"I am stronger than the obstacles in my way." "I take life one step at a time." "I trust my ability to figure things out." "I do not fear the climb; I embrace the growth." "I am rising." Martin's 3 Caring Tips for a Happier Life: Inspired by the climber's mindset, here is how to bring this resilience into your daily routine:Lighten Your Pack: A climber never carries what they don't need. Identify one "mental weight" you are carrying—a grudge, a worry about next week, or guilt from yesterday. Visualize taking it out of your backpack and leaving it on the side of the trail.The "Look Back" Rule: We are often so focused on the summit that we forget to appreciate the altitude we've already gained. If you feel stuck, stop and write down three things you have achieved in the last year.Choose Your Route: If you hit a roadblock, don't bang your head against it. Be like water and go around. Ask yourself, "What is the other way to solve this?" There is always another path up the mountain.Ready to go deeper? Access The Anxiety Circuit Breaker early here:https://calminganxietypodcast.systeme.io/letter(Use code RELAX for a launch discount)Coming Up Next: In the final episode (Part 5), we will reach The Summit to see the world from a brand new perspective.Connect with the Show: If this climb helped you find your strength, please subscribe so you don't miss the finale. Smile often, think positive thoughts, and in everything... be kind.

Brad and Tyler prepare for their favorite premium live event of the year, making predictions ahead of the WWE Royal Rumble. They workshop possible surprise entrants, a path for Sami Zayn to dethrone Drew McIntyre, and a potential farewell to AJ Styles. Later, they discuss JetSpeed's ascent within AEW and Darius Lockhart's update on ASÉ Wrestling's status.Other topics include:At the Movies: FX's "The Beauty"Bobby Hurley's ASU MeltdownSomeday, When You Have KidsFollow the show for exclusive updates.Social: @gipod19 Web: gimmickinfringementpod.com, 19mediagroup.comGoods: https://19-media-group.myspreadshop.com0:00 Intro8:10 Someday — Dogs and Dad Love14:18 Steph Watch — Revenge in Canada15:42 WWE — Royal Rumble Predictions 38:52 Promo — Bobby Hurley and ASU MBB47:21AEW — Willow's Birthday and JetSpeed's Ascent57:46 At the Movies — FX's “The Beauty”1:01:27 WDWM — ASÉ, “Skyscraper Live,” Josh and Jase, Snowpocalypse, and McCarthyism in Pittsburgh1:06:44 ClosingFollow 19 Media Group:Twitter: @19MGroupInstagram: 19mediagrouphttps://www.19MediaGroup.comDiscover our favorite podcast gear and support the show—shop our studio must-haves on our Amazon Affiliate page! https://www.amazon.com/shop/19mediagroupWant to join the conversation or invite us to your platform? Connect with us and share your vision (budget-friendly collaborations welcome)!  https://bit.ly/19Guest

S8 Ep.7 | The Great Divide: Duke's Top 5 Ascent & UNC's California NightmareTwo programs. Two trajectories. One massive gap.We're halfway through the season, and the landscape of Tobacco Road has shifted. On one side, the #5 Duke Blue Devils (17-1) are playing like the undisputed kings of the ACC. On the other hand, the #22 North Carolina Tar Heels (15-4) are licking their wounds after a defensive collapse in the Bay Area.On today's episode:The Elite Eight Miles: Duke is officially a Top 5 lock. We break down their 10-game win streak and why Jon Scheyer's squad looks like a legitimate National Title favorite.California Screaming: Will Phelan takes the Hot Seat to answer for UNC's losses to Stanford and Cal. With 170+ points allowed in one week, is the Heels' defense officially broken, or was this just a West Coast fluke?The Boozer Effect vs. The Veteran Struggle: Darryl breaks down why Duke's freshmen are succeeding where UNC's veterans are faltering.Countdown to February 7th: With the first rivalry matchup just weeks away, we ask: Is this the widest the "Great Divide" has ever been before a Duke-UNC tip-off?Join the Conversation: Who's to blame for the UNC defensive slide? Tell us in the reviews! We're at a 4.6 rating—help us hit 5.0 before the Blue Devils and Tar Heels collide.Follow Blue Blood TV:

We review the recent ASCENT-04/Keynote-D19 publication of sacituzuab govitecan + pembrolizumab for PD-L1 CPS of 10% and above TNBC compared to chemo + pembrolizumab alone. Also, a quick recap of ASCO GI earlier this month with mentions of zanidatamab and zolbetuximab. Finally, a check-in on The Pitt.

Have a Social with the Saints! Receive encouragement for your daily life as we meet & discuss St. Marianne Cope,  a role model of faith who famously cared for those with Leprosy on the Hawaiian islands. How will she help and inspire you? Be encouraged and inspired in your daily life! Get a free quote card and pamphlet of St. Marianne Cope here. We invite you to share them with friends and family. To learn more about St. Marianne Cope, click here for the official website for the Saint Marianne Cope Shrine & Museum. We want to hear from you! What struck you about St. Marianne Cope? Please send us your feedback to join the conversation by email at ministry@pilgrimcenterofhope.org The official Socials with the Saints theme song is "Hero's Ascent" by Chris Haugen. Used with permission. Thanks for listening, and remember, you are never alone in the communion of the saints! May God bless you. Help us spread hope!

Are Trump's pharmaceutical policies a seismic revolution, or just hot air? Will he succeed in lowering drug prices in 2026? Will manufacturing shift to the US? And how will all of this impact Europe and China? ING's Diederik Stadig and Stephen Farrelly answer these questions and more in this week's THINK aloud.

Greg makes real progress about ascent, and he ascends to progress. Episode 1316 Greg's new book: Inspired Imperfection Dan's new book: Confident Humility Send Questions To: Dan: @thatdankent Twitter: @reKnewOrg Facebook: ReKnew Email: askgregboyd@gmail.com Links: Greg's book:"Crucifixion of the Warrior God" Website: ReKnew.org  

In this conversation, the hosts discuss the innovative game Ascent Rivals, a fusion of racing, combat, and strategy, developed with a focus on traditional gaming experiences. The developers share their backgrounds in game development and esports, emphasising community engagement and organic growth during the alpha phase. They explore funding strategies, integrating Web3 elements, and the technical aspects of building on the Cardano blockchain, aiming to create a game that appeals to both traditional and Web3 gamers.TakeawaysAscent Rivals is a fusion game combining racing, combat, and strategy.The development team has a strong background in traditional gaming and esports.Community engagement is crucial for game development in the Web3 space.The game aims to attract traditional gamers rather than just Web3 enthusiasts.Funding comes from grants, consulting work, and self-funding.The team is focused on organic growth and community feedback during alpha testing.Web3 elements will be integrated seamlessly to enhance the player experience.The game is designed to be fun and engaging without relying on crypto incentives.Technical advancements are leveraged to achieve ambitious goals with a small team.The vision includes making Ascent Rivals a recognised esports title.Learn more about the game and join the community:https://www.ascentrivals.com/Chapters00:00Introduction to Ascent Rivals02:47Game Development Background and Vision05:58Community Engagement and Feedback08:49Funding and Development Strategy12:05Web3 Integration and Onboarding14:56Technical Aspects and Future PlansDISCLAIMER: This content is for informational and educational purposes only and is not financial, investment, or legal advice. I am not affiliated with, nor compensated by, the project discussed—no tokens, payments, or incentives received. I do not hold a stake in the project, including private or future allocations. All views are my own, based on public information. Always do your own research and consult a licensed advisor before investing. Crypto investments carry high risk, and past performance is no guarantee of future results. I am not responsible for any decisions you make based on this content.

UConn breezed through its toughest stretch in the new year, dispatching second-place Villanova with ease and then notching its largest margin of victory ever against Notre Dame. We talk about KK Arnold's continued ascent after playing the best game of her career on Monday, Sarah Strong hitting 1,000 career points and Ashlynn Shade quietly putting together another good performance. We also discuss the Huskies' 2015 and 2016 national championship teams, get into the latest updates on Morgan Cheli and Ice Brady, then take a deep dive into bracketology and future schedules. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit chasingperfection.substack.com

This week, Pastor Abraham leads us through Psalm 121, continuing our series focusing on the Psalms of Ascent.

This week, we launch into a new series, looking at the Psalms of Ascent. Pastor Abraham leads us off with Psalm 120, speaking on the song written about The God of Peace.

If you have to pick, which elite status would you prefer, American or Alaska? How does this new edit credit work? We answered these and many other questions on the Ask Us Anything hosted live on January 7th of 2026.(03:34) - ​​Curious to hear what 'coupons/credits' you just let go of, without redeeming by 12/31. I didn't use my first The Edit credit and can't stop feeling guilty.(05:48) - How does this new edit credit work, because there are so many different answers...?You can see a map of The Edit by Chase Travel℠ properties here:(10:05) - ​​What do you think about the Apple Card takeover by Chase?See Greg's old post about the Apple Card here(12:48) - Have any of you proactively lowered the credit limit on a card?(17:17) - ​Do you think that the Bilt leak is real or fake? There are 3 different leaks right nowFind coffee break episode 86 about Bilt leaks here(18:44) - ​​I started with Chase (I'm newer to points), but I'm curious what you all think are the best uses of each of the ecosystems and/or what you personally use them for?Learn more about Citi transfer partners here(23:05) - ​​Last October, I booked a stay at the Hyatt Regency Rome for mid-April 2026, not realizing it was a new hotel. The website now shows reservations starting May 1, 2026, with no availability in April. ​​I'm concerned about whether my reservation will be honored. If the hotel isn't ready, will Hyatt relocate me, and how soon would I be notified? I've booked a backup hotel, but would appreciate any tips(25:25) - Do the miles and points conventions mention things that aren't normally discussed in free podcasts like yours?(26:53) - ​​Alaska miles redemption for Europe often entails BA metal that has high fees. Any tips on European redemptions? Or are Alaska miles mainly for AA or Asian partner awards?(35:22) - ​​Does that PLAT airline credit still work for United Travel Bank this year?See our "Amex airline reimbursement fees...what still works?" post here(36:53) - ​​Venture X travel credit is a discount rather than a credit. If I have two bookings and have to cancel the one booked with the discount, can I retroactively have them lower the second booking?(37:25) - ​​What is everyone's US Bank strategy? I cashed mine out at 1.5x(42:00) - If you have to pick, which elite status would you prefer, American or Alaska?Find our podcast episode about American vs Alaska here(48:01) - Find coffee break episode 86 about Bilt leaks here(48:24) - Tim - In what cases is it worthwhile to keep both Atmos cards (Summit and Ascent)(54:10) - ​​For 2026, any new programs you're prioritizing for earning or status? E.g. Citi to PHR, Atmos, etc?Visit https://frequentmiler.com/subscribe/ to get updated on in-depth...

In the episode I discuss the Psalms of Ascent. Psalms 120-134.

Dr. Monty Pal and Dr. Hope Rugo discuss advances in antibody-drug conjugates for various breast cancer types as well as treatment strategies in the new era of oral SERDs for HR-positive breast cancer. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist and vice chair of academic affairs here at the City of Hope Comprehensive Cancer Center, Los Angeles. Today, I'm thrilled to be joined by Dr. Hope Rugo, an internationally renowned breast medical oncologist and my colleague here at City of Hope, where she leads the Women's Cancers Program and serves as division chief of breast medical oncology. Dr. Rugo is going to share with us exciting advances in antibody-drug conjugates (ADCs) that are expanding treatment options in various breast cancer types. She'll also address some of the complex questions arising in the new era of oral SERDs (selective estrogen receptor degraders) that are revolutionizing treatment in the hormone receptor-positive breast cancer space. Our full disclosures are available in the transcript of this episode.  Dr. Rugo, welcome, and thanks so much for being on the podcast today. Dr. Hope Rugo: Thank you. Pleasure to be here. Dr. Monty Pal: So, I'm going to switch to first names if you don't mind.  The first topic is actually a really exciting one, Hope, and this is antibody-drug conjugates. I don't know if I've ever shared this with you, but I actually started my training at UCLA, I was a med student and resident there, and it was in Dennis Slamon's lab. I worked very closely with Mark Pegram and a handful of others. This is right around the time I think a lot of HER2-directed therapies were really evolving initially in the clinics. Now we've got antibody-drug conjugates. Our audience is well-familiar with the mechanism there but tell us about how ADCs have really started to reshape therapy for HER2-positive breast cancer. Dr. Hope Rugo: Yeah, I mean, this is a really great place to start. I mean, we have had such major advances in breast cancer just this year, I think really changing the paradigm of treating patients. But HER2-positive disease, we've been used to having sequenced success of new agents. And I think the two biggest areas where we've made advances in HER2-positive disease, which were remarkably advanced this year in 2025, have been in antibody-drug conjugates with trastuzumab deruxtecan and with new oral tyrosine kinase inhibitors (TKIs) that have less of a target on EGFR and more on HER2, so they have an overall more tolerable toxicity profile and therefore a potentially better efficacy in the clinic. At least that's what we're seeing with these new strategies that we couldn't really pursue in the past because of toxicities of the oral TKIs. So, although our topic is ADCs, I'm going to include the TKI because it's so important in our thinking about treating HER2-positive disease. In the metastatic setting, we've seen these remarkable improvements in progression-free and overall survival in the second-line setting with T-DXd, or trastuzumab deruxtecan, compared to T-DM1. And then sequencing ADCs with giving T-DXd after T-DM1 was better than an oral tyrosine kinase or a trastuzumab combination with standard chemotherapy. That was DESTINY-Breast03 and DESTINY-Breast02. So, then we've had other trials since then, and T-DXd has moved into the early-stage setting, which I'll talk about in just a moment. But the next big trial for T-DXd in HER2-positive disease was moving it to the first-line setting to supplant what has become an established treatment for now quite a long time: the so-called CLEOPATRA regimen, which used the combined antibodies trastuzumab, pertuzumab with a taxane as first-line therapy. And then we've proceeded on with maintenance with ongoing HP for patients with responding or stable disease. And we'd seen long-term data showing, you know, at 8 years there was a group of patients whose cancers had never progressed and continued improved overall survival. So, T-DXd was studied in DESTINY-Breast09, either alone or in combination with pertuzumab compared to THP. The patient population had received a little bit more prior treatment, but interestingly, not a lot compared to CLEOPATRA. And they designed the trial to be T-DXd continued until progression with or without pertuzumab versus THP, which would go for six cycles and then stop around six cycles, and then stop and continue HP. Patients who had hormone receptor-positive disease could use hormone therapy, and this is one of the issues with this dataset because, surprisingly in this dataset and one other I'll mention, very few patients took hormone therapy. And even in the maintenance trial, the HER2CLIMB-05, less than 50% took hormone therapy as maintenance. This is kind of shocking to me and highlights an area of really important education, that outcome is improved when you add endocrine therapy for hormone receptor-positive HER2-positive metastatic disease in the maintenance phase, and it's a really important part of treatment. But suffice it to say, you know, you're kind of studying continued chemo versus stopping chemo in maintenance. And T-DXd, as we all expected, in combination with pertuzumab was superior to THP in terms of progression-free survival, really remarkably improved. And you could stop the chemo with toxicity, but most people continued it with T-DXd. Again, not a lot of people got hormone therapy, which is an issue, and you stop the chemo in the control arm. So, this has brought up a lot of interest in trying to use T-DXd as an induction and then go to maintenance, much as we do with the CLEOPATRA regimen with hormone therapy. But it brings up another issue. So first, T-DXd is superior; it's a great treatment. Not everybody needs to have it because we don't know whether it's better to give T-DXd first or second with progression - that we need a little bit longer follow-up. But just earlier this week, interestingly, the third week of December, the U.S. FDA approved T-DXd in the DESTINY-Breast09 approach with pertuzumab. So as I mentioned earlier, there was a T-DXd-alone arm; that arm has not yet reported. So very interesting, we don't know if you need pertuzumab or not. So what about the maintenance? That's the other area where we've made a huge advance here. So, we all want to stop chemo and we want to stop T-DXd. You don't want somebody being nauseated for two years while they're on treatment, and also there's a small number of patients with mostly de novo metastatic HER2-positive disease who are cured of their disease. We'd like to expand that, and I think these new drugs give us the opportunity to improve the number of patients who might be cured from metastatic disease. So the first maintenance study we saw was adding palbociclib, the CDK4/6 inhibitor, to endocrine therapy and HP, essentially. There, we had a remarkable improvement in progression-free survival difference of 15.2 months: 29 to 44 months, really huge. At San Antonio this year, we saw data with this oral tyrosine kinase inhibitor tucatinib, already showed it was great in a triplet, but as maintenance in combination with HP, it showed also a remarkable improvement in progression-free survival. But the numbers were all shifted down. So in PATINA, the control arm was in the 24-month range; here it was the tucatinib-HP arm that was in the 25 months and 16 months for control. So there was a differential benefit in ER-negative and ER-positive disease. So I think we're all thinking that our ideal approach moving forward would be to give T-DXd to most patients, we see how they do, and treat to best response. And then, stop the T-DXd, start HP, trastuzumab, pertuzumab for ER-negative, with tucatinib for ER-positive with palbociclib. We also have early data that suggests that both approaches may reduce the development of brain metastases, an issue in HER2-positive disease, and delay time to progression of brain metastases as seen in HER2CLIMB-05 in very early data - small numbers, but still quite intriguing that you might delay progression of brain metastases with tucatinib that clearly has efficacy in the brain.  So, I think that this is a hugely exciting advance for our patients, and these approaches are quickly moving into the early stage setting. T-DXd compared to standard chemo, essentially followed by THP, so a sequenced approach resulted in more pathologic complete responses than a standard THP-AC-type neoadjuvant therapy. T-DXd alone for eight cycles wasn't better, and that's interesting. We still need the sequenced non-cross-resistant chemo. But I think even more importantly, the data from DESTINY-Breast05 looking at T-DXd versus T-DM1 in patients with residual disease after neoadjuvant HER2-targeted therapy showed a remarkable improvement in invasive disease-free survival with T-DXd versus T-DM1, and quite early. It was a high-risk population, higher risk than the T-DM1 trial with KATHERINE, but earlier readout with a remarkable improvement in outcome. We expect to be FDA approved sometime in the first half of 2026. So then we'll get patients who've already had T-DXd who get metastatic disease. But my hope is that with T-DXd, maybe with tucatinib in the right group of patients or even sequenced in very high-risk disease, that we could cure many more patients with early-stage HER2-positive breast cancer and cure a subset, a greater subset of patients with de novo metastatic disease. Dr. Monty Pal: That's brilliant. And you tackled so many questions that I was going to follow up with there: brain metastases, etc. That was sort of looming in my mind. I mean, general thoughts on an ADC versus a TKI in the context of brain mets? Dr. Hope Rugo: Yeah, it's an interesting question because T-DXd has shown quite good efficacy in this setting. And tucatinib, of course, had a trial where they took patients with new brain mets, so a larger population than we've seen yet for the T-DXd trials, and saw that not only did they delay progression of brain metastases and result in shrinkage of existing untreated brain mets, but that patients who develop a new brain met, they could stay on the same assigned treatment. They got stereotactic radiation, and then the patients who were on tucatinib with trastuzumab and capecitabine had a further delay in progression of brain mets compared to those on the placebo arm, even after treatment of a new one that developed on treatment. So, I think it's hard. I think most of us for a lot of brain mets might start with the tucatinib approach, but T-DXd is also a very important treatment. You know, you're kind of trading off a diarrhea, some liver enzyme elevations with tucatinib versus nausea, which you really have to work on managing because it can be long-delayed nausea, and this risk of ILD, interstitial lung disease, that's about 12%, with most but not all trials showing a mortality rate from interstitial lung disease of just under 1 percent. In the early-stage setting, it was really interesting to see that with T-DXd getting four cycles in the neoadjuvant setting, a lot less ILD noted than the patients who got up to 14 cycles, as I think they got a median of 10 cycles in the post-surgical setting, there was a little bit more ILD. But I think we're going to be better and better at finding this earlier and preventing mortality by just stopping drug and treating earlier with steroids. Dr. Monty Pal: And this ILD issue, it always seems to resurface. There are drugs that I use in my kidney cancer clinic, everolimus, common to perhaps the breast cancer clinic as well, pembrolizumab, where I think the pattern of pneumonitis is quite different, right? What is your strategy for recognizing pneumonitis early in this context? Dr. Hope Rugo: Well, it is, and you know, having done the very early studies in everolimus where we gave it in the neoadjuvant setting and we're like, "Hmm, the patient came in with a cough. What's going on?" You know, we didn't know. And you have mouth sores, you know, we were learning about the drug as we were giving it. What we don't do with everolimus and CDK4/6 inhibitors, for example, is grade 1 changes like radiation pneumonitis, we don't stop, we don't treat it. We only treat for symptoms. But because of the mortality associated with T-DXd, albeit small, we stop drug for grade 1 imaging-only asymptomatic pneumonitis, and some of us treat with a half dose of steroids just to try and hasten recovery. We've actually now published or presented a couple of datasets from trials, a pooled analysis and a real-world analysis, that have looked at patients who were retreated after grade 1 pneumonitis or ILD and tolerated drug very well and none of them died of interstitial lung disease, which was really great to see because you can retreat safely and some of these patients stayed on for almost a year benefiting from treatment. So, there's a differential toxicity profile with these drugs and there are risk factors which clearly have identified those at higher risk: prior ILD, for example. A French group said smoking; other people haven't found that, maybe because they smoked more in France, I don't know. And being of Japanese descent is quite interesting. The studies just captured that you were treated in Japan, but I think it's probably being of Japanese descent with many drugs that increases your risk of ILD. And, you know, older patients, people who have hypoxia, those are the patients. So, how do we do this? With everolimus, we don't have specific monitoring. But for T-DXd we do; we do every nine weeks to start with and then every 12 weeks CT scans because most of the events occur relatively early. Somebody who's older and at higher risk now get the first CT at six weeks. Dr. Monty Pal: This is super helpful. And I have to tell you, a lot of these drugs are permeating the bladder cancer space which, you know, is ultimately going to be a component of my practice, so thank you for all this. We could probably stay on this topic of HER2-positive disease forever. I'm super interested in that space still. But let me shift gears a little bit and talk about triple-negative breast cancer and this evolving space of HR-positive, HER2-low breast cancer. I mean, tell us about ADCs in that very sort of other broad area. Dr. Hope Rugo: So triple-negative disease is the absolute hardest subset of disease that we have to treat because if you don't have a great response in the early stage setting, the median survival is very short, you know, under two years for the majority of TNBCs, with the exception of the small percentage of low proliferative disease subsets. The co-question is what do we do for these patients and how do we improve outcome? And sacituzumab govitecan has been one strategy in the later line setting that was shown to improve progression-free and overall survival, the Trop-2 ADC. We had recently three trials presented with the two ADCs, sacituzumab govitecan and the other Trop-2 ADC that's approved for HR-positive disease, datopotamab deruxtecan. And they were studied in the first-line setting. Two trials with SG, sacituzumab govitecan, those trials, one was PD-L1 positive, ASCENT-04. That showed that SG with a checkpoint inhibitor was superior, so pembrolizumab was superior to the standard KEYNOTE-355 type of treatment with either a taxane or gemcitabine and carboplatin with pembrolizumab for patients who have a combined positive score for PD-L1, 10 or greater. So, these are patients who are eligible for a checkpoint inhibitor, and SG resulted in an improved progression-free survival.  The interesting thing about that dataset is that few patients had received adjuvant or neoadjuvant checkpoint inhibitor, which is fascinating because we give it to everybody now. But access is an issue and timing of the study enrollment was an issue. The other thing which I think we've all really applauded Gilead for is that there was automatic crossover. So, you could get from the company, to try and overcome some of the enormous disparities worldwide in access to these life-saving drugs, you could get SG through the company for free once you had blinded independent central review confirmation of disease progression. Now, a lot of the people who got the SG got it through their insurance, they didn't bill the company, but 80 percent of patients in the control arm received SG in the second-line setting. So that impacts your ability to look at overall survival, but it's an incredibly important component of these trials. So then at ESMO, we saw the data from SG and Dato-DXd in the first-line metastatic setting for patients who either had PD-L1-negative disease or weren't eligible for an immunotherapy. For the Dato study, TROPION-Breast02, that was 10 percent of the patients who had PD-L1-positive disease but didn't get a checkpoint inhibitor, and for the ASCENT-03 trial population it was only 1 percent. Importantly, the trials allowed patients who relapsed within a year of receiving their treatment with curative intent, and the Dato study, TB-02, allowed patients who relapsed while on treatment or within the first six months, and that was 15 percent of the 20 percent of early relapsers. The ASCENT trial, ASCENT-03, had 20 percent who relapsed between 6 and 12 months. The drugs were better than standard of care chemotherapy, the ADCs in both trials, which is very nice. Different toxicity profiles, different dosing intervals, but better than standard of care chemotherapy in the disease that's hardest for us to treat. And importantly, when you looked at the subset of early relapsers, those patients also did better with the ADC versus chemotherapy, which is incredibly important. And we were really interested in that 15 percent of patients who had early relapse. I actually think that six months thing was totally contrived, invented, you know, categorization and doesn't make any sense, and we should drop it. But the early relapsers were 15 percent of TB-02 and Dato was superior to standard of care chemo. We like survival, but the ASCENT trial again allowed the crossover to an approved ADC that improved survival and 80 percent of patients crossed over. In the Dato trial, they did not allow crossover, they didn't provide Dato, which isn't approved for TNBC but is for HR-positive disease, and they didn't allow, of course, pay for SG. So very few patients actually crossed over in their post-treatment data and in that study, they were able to show a survival benefit. So actually, I think in the U.S. where we can use approved drugs already before there's a fixed FDA approval, that people are already switching to use SG or Dato in the first-line setting for metastatic TNBC that's both PD-L1 positive for SG and PD-L1 negative for both drugs. And I think understanding the toxicity profiles of the two drugs is really important as well as the dosing interval to try and figure out which drug to use. Dr. Monty Pal: Brilliant. Brilliant. Well, I'm going to shift gears a little bit. ADCs are a topic, again, just like HER2-positive disease we could stay on forever. Dr. Hope Rugo: Huge. Yes. Dr. Monty Pal: But we're going to shift gears to another massive topic, which is oral SERDs. In broad strokes, right, this utilization of CDK4/6 inhibitors in the context of HR-positive breast cancer is obviously, you know, a paradigm that's been well established at this point. Where do we sequence in oral SERDs? Where do they fit into this paradigm? Dr. Hope Rugo: Ha! This is a rapidly changing area; we keep changing what we're saying every other minute. And I think that there are three areas of great interest. So one is patients who develop ESR1 mutations that allow constitutive signaling through the estrogen receptor, even when there's not estrogen around, and that is a really important mutation that is subclonal; it develops under the pressure of treatment in about 40 percent of patients. And it doesn't happen when you first walk in the door. And what we've seen is that oral SERDs as single agents are better than standard single-agent endocrine therapy in that setting. The problem that we've had with that approach is that we're now really interested in giving targeted agents with our endocrine therapies, not just in the first-line setting where CDK4/6 inhibitors are our standard of care with survival benefit for ribociclib and, you know, survival benefit in subsets with other CDK4/6 inhibitors, and abemaciclib with a numeric improvement. So we give it first line. The question is, what do you do in the second-line setting? Because of the recent data, we now believe that oral SERDs should be really given with a targeted agent. And some datasets which were recently presented, which I think have helped us with that, have been EMBER-3 and then the most recently evERA BC, or evERA Breast Cancer, that looked at the oral SERD giredestrant with everolimus compared to standard of care endocrine therapy with everolimus, where 100 percent of patients received prior CDK4/6 inhibitor and showed a marked improvement in progression-free survival, including in the subsets of patients with a short response, 6-12 months of prior response to CDK4/6 inhibitor and in those who had a PIK3CA pathway mutation. The thing is that the benefit looks like it's much bigger in the ESR1 mutant population, although response was better, PFS wasn't better in the wild type. So, we're still trying to figure that out. We also saw EMBER-3 with imlunestrant and abemaciclib as a second line. Not everybody had had a prior CDK4/6 inhibitor; they compared it to imlunestrant alone, but still the data was quite striking and seemed to cross the need for ESR1 mutations. And then lastly, we saw data from the single arms of the ELEVATE trial looking at elacestrant with everolimus and abemaciclib and showed these really marked progression-free survival data, even though single-arm, that crossed the mutation status. At least for the everolimus combination, abemaciclib analysis is still to come in the mutated subgroups. But really remarkable PFS, much longer.  Single-agent fulvestrant after CDK4/6 inhibitor AI has a PFS in like the three-month range and in some studies, maybe close to five months. These are all at 10-plus months and really looking very good. And so those questions are, is it ESR1 mutation alone? Is it all comers? We'd like all comers, right? We believe in the combination approach and we're learning more about combinations with drugs like capivasertib and other drugs as we move forward. Everybody now wants to combine their targeted agent with an oral SERD because they're clearly here to stay with quite remarkable data. The other issue, so the second issue in the metastatic setting is, does it make a difference if we change to an oral SERD before radiographic imaging evidence of progression? And that was the question asked in the SERENA-6 trial where patients had serial monitoring for the presence of ESR1 mutations in ctDNA. And those who had them without progression on imaging could be randomized to switch to camizestrant with the same CDK4/6 inhibitor or stay on their same AI CDK4/6 inhibitor. And they showed a difference in progression-free survival that markedly favored camizestrant. But interestingly, the people who were on the standard control arm had an ESR1 mutation, we think AIs don't work, they stayed on for nine more months. The patients who were on the camizestrant stayed on for more than 16 months. And they presented some additional subset data which showed the same thing: follow-up PFS data, PFS2, all beneficial in SERENA-6 at the San Antonio [Breast Cancer Symposium]. So, we're still a little bit unclear about that. They did quality of life, and pain was markedly improved. They had a marked delayed time to progression of pain in the camizestrant arm. So this is all a work in progress, trying to understand who should we switch without progression to an oral SERD based on this development of this mutation that correlates with resistance. And, you know, it's interesting because the median time to having a mutation was 18 months and the median time to switch was almost 24 months. And then there were like more than 3,000 patients who hadn't gotten a mutation, hadn't switched, and were still okay. So screening everybody is the big question, and when you would start and who you would change on and how this affects outcome. Patients didn't have access to camizestrant in the control arm, something we can't fix but we have experimental drugs. We're actually planning a trial, I hope in collaboration with the French group Unicancer, and looking at this exact question. You know, if you switch and you change the CDK4/6 inhibitor and then you also allow crossover, what will we see? Dr. Monty Pal: We're coming right to the tail end of our time here, and I could probably go on for another couple of hours with you here. But if you could just give us maybe one or two big highlights from San Antonio, any thoughts to leave our audience with here based on this recent meeting? Dr. Hope Rugo: Yeah, I mean, I talked about a lot of those new data already from San Antonio, and the one that I'd really like to mention which I think was, you know, there were a lot of great presentations including personalized screening presented from the WISDOM trial by my colleague Laura Esserman, fascinating and really a big advance. But lidERA was the big highlight, I think, outside of the HER2CLIMB-05 which I talked about earlier in HER2-positive disease. And this study looked at giredestrant, the oral SERD versus standard of care endocrine therapy as treatment for medium and high-risk early-stage breast cancer. And what they showed, which I think was really remarkable with just about a three-year median follow-up, was an improvement in invasive disease-free survival with a hazard ratio of 0.7. I mean, really quite remarkable and so early. It looked as though this was all driven by the high-risk group, which makes sense, not the medium risk, it's too early. And also that there was a bigger benefit in patients who were on tamoxifen compared to giredestrant versus AI, but for both groups, the confidence intervals didn't cross 1. There's even a trend towards overall survival, even though it's way too early. I think that, you know, really well-tolerated oral drug that could improve outcome in early-stage disease, this is the first advance we've seen in over two decades in the treatment of early-stage hormone receptor-positive disease with just endocrine therapy. I think we think that we don't want to give up CDK4/6 inhibitors because we saw a survival benefit with abemaciclib and a trend with giving ribociclib in the NATALEE trial. So we're thinking that maybe one approach would be to give CDK4/6 inhibitors and then switch to an oral SERD or to have enough data to be able to give oral SERDs with these CDK4/6 inhibitors for early-stage disease. And that's all in the works, you know, lots of studies going on. We're going to see a lot of data with both switching 8,000 patients with an imlunestrant switching trial, an elacestrant trial going on, and safety data with giredestrant with abemaciclib and soon to come ribociclib. So, this is going to change everything for the treatment of early-stage breast cancer, and I hope cure more patients of the most common subset of the most common cancer diagnosed in women worldwide. Dr. Monty Pal: Super exciting. It's just remarkable to hear how this has evolved since 25 years ago, which is really the last time I sort of dabbled in breast cancer.  Thank you so much, Hope, for joining us today. These were fantastic insights. Appreciate you being on the ASCO Daily News Podcast and really want to thank you personally for your remarkable contribution to the field of breast cancer. Dr. Hope Rugo: Thank you very much, and thanks for talking with me today. Dr. Monty Pal: You got it. And thanks a lot to our listeners today as well. You'll find links to all the studies we discussed today in the transcript of this episode. Finally, if you value the insights that you hear today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinion of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:   Dr. Monty Pal @montypal Dr. Hope Rugo   @hoperugo Follow ASCO on social media:        ASCO on X  ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Monty Pal:    Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview   Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical   Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Hope Rugo:    Honoraria: Mylan/Viatris, Chugai Pharma   Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer   Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx  

NADAR'S BALLOON AND THE BIRTH OF PHOTOGRAPHY Colleague Anika Burgess, Flashes of Brilliance. In 1863, the photographer Nadar undertook a perilous ascent in a giant balloon to fund experiments for heavier-than-air flight, illustrating the adventurous spirit required of early photographers. This era began with Daguerre's 1839 introduction of the daguerreotype, a process involving highly dangerous chemicals like mercury and iodine to create unique, mirror-like images on copper plates. Pioneers risked their lives using explosive materials to capture reality with unprecedented clarity and permanence. NUMBER 1 1870 siege of the Paris Commune.

A reading of reflections and poems of Saint Symeon taken from various sources and translations including:~ The Book of Mystical Chapters: Meditations on the Soul's Ascent from the Desert Fathers and Other Early Christian Contemplatives, Translated by John Anthony McGuckin~ The Enlightened Heart: An Anthology of Sacred Poetry, by Stephen Mitchell~ The Fire rises in Me - English version by Ivan M. GrangerSaint Symeon the New Theologian (949 -1022 AD) was an Eastern Orthodox monk and poet who was one of the three saints canonized by the Eastern Orthodox Church and given the title of "Theologian." "Theologian" was not applied to Symeon in the modern academic sense of theological study; the title was intended only to recognise someone who spoke from personal experience of the vision of God. One of his principal teachings was that humans could and should experience theoria (literally "contemplation," or direct experience of God).Symeon was born into the Byzantine nobility and given a traditional education. At age fourteen, he met Symeon the Studite, a renowned monk of the Monastery of Stoudios in Constantinople, who convinced him to give his own life to prayer and asceticism under the elder Symeon's guidance. By the time he was thirty, Symeon the New Theologian became the abbot of the Monastery of Saint Mamas, a position he held for twenty-five years. He attracted many monks and clergy with his reputation for sanctity, though his teachings brought him into conflict with church authorities, who would eventually send him into exile. Symeon is recognized as the first Eastern Christian mystic to share his own mystical experiences freely. Some of his writings are included in the Philokalia, a collection of texts by early Christian mystics on contemplative prayer and hesychast teachings. Symeon wrote and spoke frequently about the importance of experiencing directly the grace of God, often talking about his own experiences of God as divine light. Another common subject in his writings was the need of putting oneself under the guidance of a spiritual father. The authority for many of his teachings derived from the traditions of the Desert Fathers, early Christian monks and ascetics. Symeon's writings include Hymns of Divine Love, Ethical Discourses, and The Catechetical Discourses.Photography: George Digalakis ~ The Sound of Silence  / georgedigalakisphotography  https://www.digalakisphotography.com/Music: "Let My Love Be Heard" by Jake Runestad. Performed by the Bob Cole Conservatory Chamber Choir.   • Let My Love Be Heard - Jake Runestad  Cousin Silas - Slow Rotations https://cousinsilas1.bandcamp.com/With thanks to Pat for his kind permission to use his music for this channel.

The final stages of the expedition to summit Denali were grueling for Walter Harper and the rest of the team. And after that accomplishment, Harper's life was tragically short. Research: Bishop, Click. “Sponsor Statement SB-144 – Walter Harper Day.” Alaska State Legislature. https://www.akleg.gov/basis/get_documents.asp?session=31&docid=58198 Dean, Patrick. “How Hudson Stuck's Ascent of Denali Boosted Recognition of Indigenous Alaskans.” History News Network. 12/13/2020. https://www.hnn.us/article/how-hudson-stucks-ascent-of-denali-boosted-recogni Denali National Park and Preserve. “Superintendent Harry Karstens.” https://www.nps.gov/dena/learn/photosmultimedia/station06a.htm Ehrlander, Mary. “Walter Harper, Alaska Native Son.” UAF Summer Sessions & Lifelong Learning. Via YouTube. 7/7/2018. https://www.youtube.com/watch?v=9-FrvS3gONg Farquhar, Francis P. “Henry P. Karstens—1878-1955.” The American Alpine Club. https://publications.americanalpineclub.org/articles/12195611200/Henry-P-Karstens-1878-1955 Hayes, Alan L. “One Congregation, Two Cultures: St. Mark’s Episcopal Church Nenana, Alaska.” Anglican and Episcopal History, vol. 68, no. 1, 1999, pp. 141–46. JSTOR, http://www.jstor.org/stable/42612013. Accessed 24 Nov. 2025. James, David A. “In story of the legendary ‘Walter Harper: Alaska Native Son,’ Denali is just the beginning.” Alaska Daily News. 12/16/2017. https://www.adn.com/arts/books/2017/12/16/in-story-of-the-legendary-walter-harper-alaska-native-son-denali-is-just-the-beginning/ James, David. “The Brief, But Bright Story of Walter Harper.” Alaska. 5/21/2022. https://alaskamagazine.com/authentic-alaska/the-brief-but-bright-story-of-walter-harper/ John, Peter. “The Gospel According to Peter John.” Krupa, David J., editor. Alaska Native Knowledge Network. 1996. https://ankn.uaf.edu/publications/Books/Peter_John.pdf Johnson, Erik. “Honoring the Unsung Heroes of the 1913 Summit Expedition: Esaias George and John Fredson.” National Park Service. https://www.nps.gov/articles/000/dena-history-unsung-heroes.htm Johnson, Erik. “The Ultimate Triumph and Tragedy: Remembering Walter Harper 100 Years Later.” National Park Service. Denali National Park. https://www.nps.gov/articles/dena-history-harper.htm Manville, Julie and Ross Maller. “The Influence of Christian Missionaries on Alaskan Indigenous Peoples.” Interdisciplinary Journal of Research on Religion. Vol. 5, Article 8. 2009. Miller, Matt. “‘May Light Perpetual Shine Upon Them.’” KTOO. https://www.ktoo.org/2013/10/26/may-light-perpetual-shine-upon-them/ New York Times. “Yukon Indian Opens Coney Island Eyes.” 6/1/1914. Stuck, Hudson. “A winter circuit of our Arctic coast; a narrative of a journey with dog-sleds around the entire Arctic coast of Alaska.” New York. C. Scribner’s Sons. 1920. https://archive.org/details/wintercircuito00stuc/ Stuck, Hudson. “Ten Thousand Miles With A Dog Sled a Narrative of winter travel in Interior Alaska.” 1917. https://archive.org/details/tenthousandmiles0000huds/ Stuck, Hudson. “The ascent of Denali (Mount McKinley) a narrative of the first complete ascent of the highest peak in North America.” New York, C. Scribner's Sons. 1914. https://archive.org/details/ascentofdenalimo01stuc/ Stuck, Hudson. “Voyages on the Yukon and its tributaries: a narrative of summer travel in the interior of Alaska.” New York : Charles Scribner's Sons. 1917. https://archive.org/details/cihm_76545/ Walker, Tom. “A Brief Account of the 1913 Climb of Mount McKinley.” Denali National Park and Preserve. https://www.nps.gov/dena/learn/historyculture/1913ex.htm Woodside, Christine. “Who Led the First Ascent of Denali? Hudson Stuck, Archdeacon of the Yukon.” Vol. 63, No., 2 Summer/Fall 2012. See omnystudio.com/listener for privacy information.

While working as a guide in his youth, Walter Harper met and worked for a man named Hudson Stuck. Their friendship would lead to Walter becoming the first person to reach the summit of Denali. Research: Bishop, Click. “Sponsor Statement SB-144 – Walter Harper Day.” Alaska State Legislature. https://www.akleg.gov/basis/get_documents.asp?session=31&docid=58198 Dean, Patrick. “How Hudson Stuck's Ascent of Denali Boosted Recognition of Indigenous Alaskans.” History News Network. 12/13/2020. https://www.hnn.us/article/how-hudson-stucks-ascent-of-denali-boosted-recogni Denali National Park and Preserve. “Superintendent Harry Karstens.” https://www.nps.gov/dena/learn/photosmultimedia/station06a.htm Ehrlander, Mary. “Walter Harper, Alaska Native Son.” UAF Summer Sessions & Lifelong Learning. Via YouTube. 7/7/2018. https://www.youtube.com/watch?v=9-FrvS3gONg Farquhar, Francis P. “Henry P. Karstens—1878-1955.” The American Alpine Club. https://publications.americanalpineclub.org/articles/12195611200/Henry-P-Karstens-1878-1955 Hayes, Alan L. “One Congregation, Two Cultures: St. Mark’s Episcopal Church Nenana, Alaska.” Anglican and Episcopal History, vol. 68, no. 1, 1999, pp. 141–46. JSTOR, http://www.jstor.org/stable/42612013. Accessed 24 Nov. 2025. James, David A. “In story of the legendary ‘Walter Harper: Alaska Native Son,’ Denali is just the beginning.” Alaska Daily News. 12/16/2017. https://www.adn.com/arts/books/2017/12/16/in-story-of-the-legendary-walter-harper-alaska-native-son-denali-is-just-the-beginning/ James, David. “The Brief, But Bright Story of Walter Harper.” Alaska. 5/21/2022. https://alaskamagazine.com/authentic-alaska/the-brief-but-bright-story-of-walter-harper/ John, Peter. “The Gospel According to Peter John.” Krupa, David J., editor. Alaska Native Knowledge Network. 1996. https://ankn.uaf.edu/publications/Books/Peter_John.pdf Johnson, Erik. “Honoring the Unsung Heroes of the 1913 Summit Expedition: Esaias George and John Fredson.” National Park Service. https://www.nps.gov/articles/000/dena-history-unsung-heroes.htm Johnson, Erik. “The Ultimate Triumph and Tragedy: Remembering Walter Harper 100 Years Later.” National Park Service. Denali National Park. https://www.nps.gov/articles/dena-history-harper.htm Manville, Julie and Ross Maller. “The Influence of Christian Missionaries on Alaskan Indigenous Peoples.” Interdisciplinary Journal of Research on Religion. Vol. 5, Article 8. 2009. Miller, Matt. “‘May Light Perpetual Shine Upon Them.’” KTOO. https://www.ktoo.org/2013/10/26/may-light-perpetual-shine-upon-them/ New York Times. “Yukon Indian Opens Coney Island Eyes.” 6/1/1914. Stuck, Hudson. “A winter circuit of our Arctic coast; a narrative of a journey with dog-sleds around the entire Arctic coast of Alaska.” New York. C. Scribner’s Sons. 1920. https://archive.org/details/wintercircuito00stuc/ Stuck, Hudson. “Ten Thousand Miles With A Dog Sled a Narrative of winter travel in Interior Alaska.” 1917. https://archive.org/details/tenthousandmiles0000huds/ Stuck, Hudson. “The ascent of Denali (Mount McKinley) a narrative of the first complete ascent of the highest peak in North America.” New York, C. Scribner's Sons. 1914. https://archive.org/details/ascentofdenalimo01stuc/ Stuck, Hudson. “Voyages on the Yukon and its tributaries: a narrative of summer travel in the interior of Alaska.” New York : Charles Scribner's Sons. 1917. https://archive.org/details/cihm_76545/ Walker, Tom. “A Brief Account of the 1913 Climb of Mount McKinley.” Denali National Park and Preserve. https://www.nps.gov/dena/learn/historyculture/1913ex.htm Woodside, Christine. “Who Led the First Ascent of Denali? Hudson Stuck, Archdeacon of the Yukon.” Vol. 63, No., 2 Summer/Fall 2012. See omnystudio.com/listener for privacy information.